巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02367 巨子生物

已收盘 04-27 16:08:30

31.320

-0.980

-3.03%

最高32.500	最低31.120	成交量695.10万
今开32.260	昨收32.300	日振幅4.27%
总市值332.62亿	流通市值332.62亿	总股本10.62亿
成交额2.19亿	换手率0.65%	流通股本10.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":31.32,"timestamp":1777277310004,"preClose":32.3,"halted":0,"volume":6951018,"delay":0,"changeRate":-0.0303405572755417,"floatShares":1061999999,"shares":1061999999,"eps":1.809999,"marketStatus":"已收盘","change":-0.98,"latestTime":"04-27 16:08:30","open":32.26,"high":32.5,"low":31.12,"amount":219114246,"amplitude":0.042724,"askPrice":31.34,"askSize":5000,"bidPrice":31.32,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":2.014185,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":5,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":32.3,"dividendRate":0.019771,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":0.713129,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"2629048015","title":"【券商聚焦】华泰研究维持巨子生物(02367)“买入”评级 看好新品销售及医美进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048015","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629048015?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:39","pubTimestamp":1776847155,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰研究发布研报指，巨子生物 核心看点在于新品推出带来的销售改善以及医美业务取得实质性进展，预期公司将于2026年重回增长轨道。该行维持对巨子生物的“买入”评级及目标价45港元。研报认为，可复美品牌自2025年6月起进入低基数阶段，新品的市场表现及其胶原系列、焦点系列等现有产品的销售节奏值得持续跟踪。盈利预测方面，华泰研究维持对巨子生物2026年至2028年的归母净利润预测，分别为19.33亿元、21.27亿元及23.02亿元人民币。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979650","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629090949","title":"国货美妆品牌抢占线下折扣店","url":"https://stock-news.laohu8.com/highlight/detail?id=2629090949","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629090949?lang=zh_cn&edition=full","pubTime":"2026-04-22 15:24","pubTimestamp":1776842640,"startTime":"0","endTime":"0","summary":"国货美妆品牌抢占线下折扣店","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713962495.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713962495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","301371","LU0593848301.USD","603605","BK1207","IE0005HP3H50.USD","BK0188","300957","BK0070","BK0239","LU2488822045.USD","LU1820825898.SGD","BK0229","BK0012","BK0028","BK0196","600315","BK0273","LU1146622755.USD","02367","LU2460026573.USD","SG9999004311.SGD","LU1997245177.USD","688363","600223","LU0274383008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703720","title":"港股异动 | 巨子生物(02367)再涨超7% 央视深度探厂巨子生物 机构看好公司新产品及新业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629703720?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:58","pubTimestamp":1776736706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，巨子生物再涨超7%，截至发稿，涨5.8%，报31.38港元，成交额1.89亿港元。考虑到公司两款三类医疗器械“重组 I 型α1 亚型胶原蛋白冻干纤维”、“重组 I 型α1 亚型胶原蛋白及透明质酸钠复合溶液产品”陆续获批，展现其持续领先的创新能力及战略定力。后续两款医美产品的陆续商业化、以及多款妆类新品的上市值得期待，建议持续关注公司新产品和新业务进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","VXUS","LU2488822045.USD","BK1207","SG9999004311.SGD","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186424486","title":"异动解读 | 巨子生物盘中大涨5.26%，回购注销与医美商业化预期提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186424486","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186424486?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:41","pubTimestamp":1776735662,"startTime":"0","endTime":"0","summary":"巨子生物今日盘中大涨5.26%，引起了市场的广泛关注。消息面上，公司近期迎来多重利好。一方面，公司公告注销了920万股已回购股份，回购总金额约3.22亿港元，此举有助于减少已发行股本，从而提升每股价值。另一方面，公司多款三类医疗器械注册证成功获批，医美产品即将步入商业化阶段，有望开启第二增长曲线，公司战略正向“多品牌、多品类、多渠道”转型，强化自营体系。回购注销叠加医美商业化预期，共同提振了市场对公司未来发展的信心，推动了股价在盘中的显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174562796","title":"巨子生物回购920万股股份，涉资约3.22亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174562796","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174562796?lang=zh_cn&edition=full","pubTime":"2026-04-20 18:26","pubTimestamp":1776680787,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司（股票代码：02367）于2026年4月20日公告，期间自2025年12月至2026年1月间多次回购合计9,200,000股普通股，并于2026年4月20日完成注销。该批股份占回购前已发行股本约0.86%，每股回购价介乎港币33.60元至36.07元，总金额约3.22亿港元。\n回购完成后，公司已发行股本由1,070,904,000股减少至1,061,704,000股，库藏股数为零。公司同时确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由执行董事兼联席公司秘书严鈺博签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628741201","title":"巨子生物(02367)注销920万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628741201","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628741201?lang=zh_cn&edition=full","pubTime":"2026-04-20 18:25","pubTimestamp":1776680738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，巨子生物(02367)发布公告，于2026年4月20日，该公司注销920万股已回购股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999004311.SGD","02367","LU2488822045.USD","BK1207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628714764","title":"巨子生物(02367)逆市上扬3.20% 中信建投指其医美产品即将步入商业化阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2628714764","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628714764?lang=zh_cn&edition=full","pubTime":"2026-04-20 14:43","pubTimestamp":1776667439,"startTime":"0","endTime":"0","summary":"金吾财讯 | 巨子生物 逆市上扬，截至发稿，报29.68港元，涨幅3.20%，成交额1.60亿港元。消息面上，中信建投证券研究指，巨子生物多款三类医疗器械注册证成功获批，医美产品即将步入商业化阶段，有望开启第二增长曲线。展望2026：1)重点关注III类医美器械产品上市及渠道放量；2)战略向“多品牌、多品类、多渠道”转型，强化自营体系。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979421","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601066","02367","LU2488822045.USD","BK1207","SG9999004311.SGD","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170852498","title":"异动解读 | 巨子生物盘中大涨5.49%，年度业绩发布后市场情绪修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1170852498","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170852498?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:09","pubTimestamp":1776654563,"startTime":"0","endTime":"0","summary":"巨子生物今日盘中股价大幅上涨5.49%，引起了市场的广泛关注。消息面上，巨子生物近日发布了年度业绩报告。报告显示，公司全年实现营收55.19亿元，同比微降0.4%；归母净利润19.15亿元，同比下滑7.2%。这是公司上市以来首次出现营收与净利润未能延续双位数增长的情况。核心品牌可复美收入也同比有所下降。尽管业绩出现下滑，但市场认为实际降幅较为温和，且公司的绝对利润水平仍然可观。此前公司市值已出现较大幅度回落，盘面表现或反映了市场在充分消化业绩利空消息后，情绪得到修复和提振。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627025065","title":"消费板块上扬 沪上阿姨(02589)涨6.50%、奈雪的茶(02110)涨2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627025065","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627025065?lang=zh_cn&edition=full","pubTime":"2026-04-16 10:32","pubTimestamp":1776306768,"startTime":"0","endTime":"0","summary":"金吾财讯 | 消费板块上扬，沪上阿姨 涨6.50%，奈雪的茶涨2.53%，泡泡玛特涨2.33%，巨子生物涨1.47%，上美股份涨1.19%，小米集团-W涨1.23%，名创优品涨0.97%。国信证券表示，节后以来零售及美护板块出现较多回调，主要系外围事件冲击下，大盘风险偏好下行，板块情绪走弱；同时基本面在节日错期和投放趋于谨慎，以及去年基数较高等因素下略有承压。但我们认为阶段性回调也为后续优质龙头的反弹积蓄了势能。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001093.SGD","BK1615","IE00B3M56506.USD","LU1303224171.USD","LU0359201885.HKD","LU0214875030.USD","LU0084288322.USD","LU0235996351.USD","LU0345776255.USD","LU1794554557.SGD","LU1023057109.AUD","BK1506","LU0531971595.HKD","IE0034224299.USD","BK1224","LU0359201612.USD","LU0823426480.USD","LU0348735423.USD","LU0708995583.HKD","LU1323998911.USD","LU0254981946.USD","LU1770034418.SGD","LU0348827113.USD","LU0117841782.USD","02145","BK1523","LU0051755006.USD","LU0348767384.USD","LU0231483743.USD","SGXZ62798434.SGD","LU0502904849.HKD","LU0531970944.HKD","LU2097828805.USD","BK1618","LU0244354667.USD","MNSO","IE0032431581.USD","LU0650527681.SGD","LU2476274308.USD","LU0143863784.USD","LU0823426308.USD","SG9999004311.SGD","LU0039217434.USD","LU0052750758.USD","LU0348816934.USD","LU0327786744.USD","LU0499858438.USD","LU0918141705.HKD","LU0823038988.USD","LU2097828474.EUR","LU0348814723.USD","LU0823041008.USD","LU1813983027.USD","BK1246","02150","01810","LU2097828557.USD","LU0348766576.USD","LU2242644610.SGD","LU2476274720.SGD","LU0605514214.HKD","HXXD.SI","LU2257852520.SGD","LU0594300419.USD","LU0823413660.USD","BK1521","LU0594300179.USD","LU0417516738.SGD","LU0455707207.USD","LU0417516902.SGD","LU2294711473.HKD","LU1481107354.HKD","LU1868838027.USD","02367","LU0675040207.SGD","LU0572944931.SGD","81810","LU0561508036.HKD","LU1282648689.USD","LU1770036033.HKD","LU2087589342.USD","BK1610","LU0456827905.SGD","09992","LU1868837565.USD","LU0871576103.HKD","LU0823040885.USD","LU0611395673.USD","HK0000286598.CNH","LU0345775950.USD","BK1249","LU0149721374.USD","SG9999002950.SGD","LU2097828714.EUR","BK1502","LU0441854154.USD","BK1233","LU0449515922.USD","LU2097828631.EUR","BK4588","LU1720050803.USD","BK1193","LU0164865239.USD","LU0797268264.HKD","LU0823397103.USD","LU0823039010.USD","LU0634319403.HKD","LU0164872284.USD","BK1607","LU0054450605.USD","LU2152927971.USD","LU0143863198.USD","LU0320764599.SGD","PMRTY","HK0000165453.HKD","LU0463099449.HKD","02589","LU0326950275.SGD","XIACY","LU1981816686.USD","LU0456846285.SGD","09896","LU1956131251.USD","LU0211977185.USD","LU0918141887.USD","LU1188198961.HKD","LU0359202008.SGD","LU0593848301.USD","LU1105468828.SGD","LU0210526637.USD","LU2488822045.USD","LU1961090484.USD","BK1575","LU2778985437.USD","LU2543165471.USD","SG9999001069.SGD","MIUmain","LU2399975544.HKD","BK1616","SGXZ86797644.SGD","BK1207","LU0169518387.USD","LU0499858602.USD","LU0823413587.USD","LU0348825331.USD","LU1719994722.HKD","SG9999003461.SGD","BK1587","LU0164880469.USD","LU0700851271.USD","LU0823397285.USD","BK4585","LU2226246903.HKD","LU1328277881.USD","LU1880383440.USD","LU0314109678.HKD","LU0449509016.USD","LU2039709279.SGD","LU1251922891.USD","SG9999002463.SGD","LU0540923850.HKD","BK1589","LU1808992512.USD","LU0307460666.USD","LU1880383366.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912598","title":"巨子生物(02367)委任欧阳丽妮为公司联席秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912598","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625912598?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:29","pubTimestamp":1775640592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，巨子生物(02367)发布公告，袁颕欣女士(袁女士)辞任本公司联席公司秘书及不再担任根据香港联合交易所有限公司证券上市规则第3.05条所规定的本公司授权代表，及根据香港法例第622章公司条例在香港代表接收法律程序文件而言的本公司香港法律程序文件代理人(法律程序文件代理人)，自2026年4月8日起生效。在袁女士辞任后，董事会欣然宣布委任欧阳丽妮女士(欧阳女士)为本公司公司联席秘书、授权代表及法律程序文件代理人，均自2026年4月8日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1207","SG9999004311.SGD","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624650049","title":"增长失速、财富“腰斩”，医美富豪们正在失去“玻尿酸权杖”","url":"https://stock-news.laohu8.com/highlight/detail?id=2624650049","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624650049?lang=zh_cn&edition=full","pubTime":"2026-04-03 20:59","pubTimestamp":1775221178,"startTime":"0","endTime":"0","summary":"潮水退去，方知成色。2025年医美财报集体告别“高增长神话”，标志着行业正式由红利驱动的野蛮生长，步入存量博弈与逻辑重构的深度调整周期。据最新披露的业绩数据，头部企业利润出现普遍下滑。玻尿酸领域，爱美客遭遇上市后首次营收、净利双双负增长，扣非净利同比下滑超40%；昊海生科净利同比大跌40.3%。胶原蛋白赛道亦未能幸免，巨子生物录得上市后首次营收利润双降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033695172192.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695172192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999004311.SGD","BK1207","02367","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197449508","title":"巨子生物3月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1197449508","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197449508?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:35","pubTimestamp":1775118948,"startTime":"0","endTime":"0","summary":"巨子生物于2026年4月2日发布3月股份变动月报表。公告显示，截至2026年3月31日，公司法定股本保持在5,000,000,000股普通股，面值每股USD 0.00001，注册资本USD 50,000，较上月底无变化。公告同时披露，曾于2025年6月13日购回的9,200,000股尚未注销，但本月并未对已发行股本造成影响。公告进一步表示，公司已确认符合香港联交所对上市公司的相关监管要求。该公告由执行董事兼联席公司秘书严鈺博签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","BK0028","LU0405327494.USD","BK1515","BK1564","06160","BK1161","LU1115378108.SGD","01789","LU0634319403.HKD","LU1255011170.USD","LU2488822045.USD","BK1191","BK0012","LU1328615791.USD","02196","06821","BK1588","LU1719994722.HKD","LU2495084118.USD","LU1303224171.USD","LU0348783233.USD","BK1617","02268","LU0348735423.USD","LU0405327148.USD","600030","06030","LU2148510915.USD","BK1100","01530","09688","HK0000165453.HKD","IE00B543WZ88.USD","LU1969619763.USD","02228","01099","03933","LU0307460666.USD","02367","BK1583","LU1997245177.USD","LU2476274308.USD","BK0276","LU2399975544.HKD","LU1770034418.SGD","BK1593","IE00BPRC5H50.USD","LU0348766576.USD","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622028727","title":"【券商聚焦】国金证券维持巨子生物(02367)“买入”评级 指短期业绩承压但核心产品力稳固","url":"https://stock-news.laohu8.com/highlight/detail?id=2622028727","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622028727?lang=zh_cn&edition=full","pubTime":"2026-03-25 15:38","pubTimestamp":1774424333,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券发布研报指，巨子生物 2025年业绩短期承压，但核心产品力与品牌力依然稳固。报告期内，公司实现总收入人民币55.2亿元，同比基本持平；实现净利润人民币19.1亿元，同比下降7.1%。品牌可丽金期内收入人民币9.2亿元，同比增长9.2%，展现出较强韧性，增长得益于核心单品胶原大膜王成功迭代至3.0版本及线上渠道拓展。销售及经销开支同比增长2.4%至人民币20.6亿元，费用率有所提升。该行维持对巨子生物的“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977258","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119602796","title":"异动解读 | 巨子生物盘中大跌5.08%，因业绩下滑及短期舆论冲击","url":"https://stock-news.laohu8.com/highlight/detail?id=1119602796","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119602796?lang=zh_cn&edition=full","pubTime":"2026-03-23 14:12","pubTimestamp":1774246369,"startTime":"0","endTime":"0","summary":"巨子生物今日盘中大跌5.08%，引起了市场的广泛关注。消息面上，公司发布的年度业绩显示，期内实现营业收入55.19亿元，同比下降0.37%；归母净利润19.15亿元，同比下降7.15%。同时，短期舆论对公司销售造成了冲击，加之行业竞争加剧，共同影响了投资者情绪。中金发表报告指出，基于外部冲击影响及竞争加剧，下调了巨子生物2026-2027年的净利润预测，维持“跑赢行业”评级，但将目标价下调13%至49港元。东吴证券也表示，考虑到行业竞争加剧及短期舆论影响，下调了对公司未来两年的盈利预测，但维持“买入”评级，认为公司作为重组胶原蛋白领域的龙头，长期地位依然突出。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621572245","title":"中金：降巨子生物(02367)目标价至49港元 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2621572245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621572245?lang=zh_cn&edition=full","pubTime":"2026-03-23 13:59","pubTimestamp":1774245586,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基于外部冲击影响及竞争加剧，下调巨子生物(02367)2026-2027年净利润预测各10%、10%至19.2亿及21.5亿元人民币，维持“跑赢行业”评级，基于盈利预测及板块估值中枢变化，下调目标价13%至49港元。巨子生物2025年业绩符合该行预期。收入55.2亿元人民币，同比跌0.4%，净利润19.2亿元人民币，同比跌7.2%，经调整净利润19.6亿元人民币，同比跌8.9%，业绩符合该行预期。同时公司公布2025年末期股息每股0.54元人民币和特别股息0.67元人民币，合计分红比例67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","BK1197","BK1574","LU2476274720.SGD","LU0348827113.USD","LU2778985437.USD","BK1207","BK1161","LU0417516902.SGD","CXO","06821","LU0540923850.HKD","LU0348784397.USD","LU1303224171.USD","01530","LU2476274308.USD","BK1141","BK1617","LU2328871848.SGD","02196","BK1583","02268","LU0417516571.SGD","02367","LU0634319403.HKD","IE00BPRC5H50.USD","LU1770034418.SGD","02228","LU0307460666.USD","LU0417516738.SGD","01789","09926","BK1585","03933","LU1719994722.HKD","LU1794554557.SGD","06160","BK1588","BK1191","LU2488822045.USD","LU0348735423.USD","LU1115378108.SGD","BK1500","09688","BK1593","01099","IE00B543WZ88.USD","LU0348767384.USD","LU2399975544.HKD","03329"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621434857","title":"【东吴商社吴劲草团队】巨子生物 |2025年年报点评：胶原医美获批打开成长新空间，期待26年业绩回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2621434857","media":"草叔消费升级研究","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621434857?lang=zh_cn&edition=full","pubTime":"2026-03-22 20:53","pubTimestamp":1774183980,"startTime":"0","endTime":"0","summary":"主品牌表现分化：分品牌看，2025年可复美/可丽金分别实现收入44.7/9.2亿元，同比分别-1.6%/+9.2%，收入占比分别为81.0%/16.6%。盈利预测与投资评级：公司作为我国重组胶原蛋白领域的龙头，护肤领域品牌力和产品力基本盘稳固，医美领域两款新品获批上市，有望打开成长空间。短期舆论导致业绩波动，但长期公司龙头地位突出，期待26年业绩逐渐回暖，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzIwMjU2Nzg0MQ==&mid=2247556063&idx=2&sn=621b04f356970b07a103fd5ee0a5ead9&chksm=97d6a3351062c053858d0125503747c12a933193be9919f8be16d55ea75ccd84147a625d8b04&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2488822045.USD","SG9999004311.SGD","BK1207","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620734490","title":"官宣孵化“利妍”新品牌，巨子生物“医美第一枪”如何打响？","url":"https://stock-news.laohu8.com/highlight/detail?id=2620734490","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620734490?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:04","pubTimestamp":1774015468,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者凌晨报道经历多年爆发式红利期后，重组胶原蛋白赛道正处于增速回归的转折点。3月19日，巨子生物交出了一份略显沉重的2025财年答卷。据悉，该公司全年实现营收55.18亿元，同比微降0.4%；净利润19.14亿元，同比下降7.1%。这是巨子生物上市以来首次出现营收与利润的双重失速。过去一年，巨子生物在资本市场经历了剧烈的估值重塑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603203679228390.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603203679228390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1207","02367","LU2488822045.USD","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620882547","title":"花旗：料巨子生物(02367)下半年有望复苏 目标价降至37港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620882547","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620882547?lang=zh_cn&edition=full","pubTime":"2026-03-20 15:05","pubTimestamp":1773990340,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，巨子生物2025年净利润下跌7%，符合公司去年12月指引的中高个位数跌幅，并与该行预期一致。考虑到销售及利润率展望低于预期，花旗下调对巨子生物的今明两年盈利预测8%及13%，目标价由44.6港元下调至37港元，基于2026年预测市盈率18倍，估值处于低谷，料今年下半年有望复苏，维持“买入”评级。花旗预计2026年毛利率将因产品组合转变及原材料成本上升而轻微收缩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":0.1231},{"period":"1month","weight":0.0846},{"period":"3month","weight":-0.0511},{"period":"6month","weight":-0.225},{"period":"1year","weight":-0.5761},{"period":"ytd","weight":-0.0294}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家主要从事基于生物活性成分的美丽与健康产品的研发、制造及销售业务的投资控股公司。该公司的主要产品包括功效性护肤品、医用敷料等专业皮肤护理产品，以及保健食品及其他产品。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.063759},{"month":2,"riseRate":0.75,"avgChangeRate":0.082298},{"month":3,"riseRate":0.75,"avgChangeRate":0.049732},{"month":4,"riseRate":0.75,"avgChangeRate":0.042841},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.050236},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.053764},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.046799},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018731},{"month":9,"riseRate":0.666667,"avgChangeRate":0.061782},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.126143},{"month":11,"riseRate":0.333333,"avgChangeRate":0.019827},{"month":12,"riseRate":0.25,"avgChangeRate":0.047101}],"exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}